A79809
5-氨基水杨酸
95%
别名:
5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸
登录 查看公司和协议定价
选择尺寸
关于此项目
线性分子式:
H2NC6H3-2-(OH)CO2H
化学文摘社编号:
分子量:
153.14
Beilstein:
2090421
EC 号:
MDL编号:
UNSPSC代码:
12352106
PubChem化学物质编号:
NACRES:
NA.22
方案
95%
表单
powder with small lumps
反应适用性
reaction type: solution phase peptide synthesis
mp
275-280 °C (dec.) (lit.)
应用
detection
peptide synthesis
SMILES字符串
Nc1ccc(O)c(c1)C(O)=O
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
基因信息
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
相关类别
应用
5-氨基水杨酸是适用于ELISA分析的过氧化物酶底物。这一底物产生可溶性的棕色终产物，可在450nm处通过分光光度法读取。使用3 N NaOH可终止反应并在550 nm处读取结果。
警示用语：
Warning
危险分类
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
靶器官
Respiratory system
储存分类代码
13 - Non Combustible Solids
WGK
WGK 2
闪点(°F)
No data available
闪点(°C)
No data available
个人防护装备
dust mask type N95 (US), Eyeshields, Gloves
B Flourié et al.
Alimentary pharmacology & therapeutics, 37(8), 767-775 (2013-03-05)
Aminosalicylates are first-choice treatment for mild-to-moderately active ulcerative colitis (UC); however, multi-dosing regimens are inconvenient. To compare the efficacy and safety of once- (OD) vs. twice- (BD) daily prolonged-release mesalazine (Pentasa, Ferring, Saint-Prex, Switzerland) for active mild-to-moderate UC in a
John K Marshall et al.
The Cochrane database of systematic reviews, (1)(1), CD004115-CD004115 (2010-01-22)
5-Aminosalicylates (5-ASA) are considered a first-line therapy for inducing and maintaining remission of mild to moderately active ulcerative colitis (UC). When inflammation in UC is limited to the distal colon, 5-ASA can also be administered rectally as a suppository, enema
Roja Rahimi et al.
Digestive diseases and sciences, 54(4), 712-721 (2008-08-07)
5-Aminosalicylates are the standard treatment for induction and maintenance of remission in mild-to-moderate ulcerative colitis. In recent years, the 5-aminosalicylic acid-containing pro-drug balsalazide has been the focus of attention. To compare the efficacy and tolerance of balsalazide and mesalazine by
W Kruis et al.
Alimentary pharmacology & therapeutics, 37(7), 680-690 (2013-02-19)
Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse. To investigate mesalazine (Salofalk granules) in this setting. In a double-blind, placebo-controlled, multicentre, 6-week trial, patients were randomised to mesalazine 1000 mg three times daily or placebo.
Christian P Selinger et al.
Inflammatory bowel diseases, 19(10), 2199-2206 (2013-08-01)
Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持